Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2008-01-01
2008-01-01
Ksihore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C514S449000, C514S510000
Reexamination Certificate
active
10239598
ABSTRACT:
Liposomal-encapsulated taxane or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer. The liposomal encapsulated paclitaxel allows for administration to a patient, particularly a human patient, in less than one hour without substantial toxicity.
REFERENCES:
patent: 4534899 (1985-08-01), Sears
patent: 4861580 (1989-08-01), Janoff et al.
patent: 4898735 (1990-02-01), Barenholz et al.
patent: 4927571 (1990-05-01), Huang et al.
patent: 4952408 (1990-08-01), Rahman
patent: 4960790 (1990-10-01), Stella et al.
patent: 5041278 (1991-08-01), Janoff et al.
patent: 5059591 (1991-10-01), Janoff et al.
patent: 5094854 (1992-03-01), Ogawa et al.
patent: 5234634 (1993-08-01), Janoff et al.
patent: 5330689 (1994-07-01), Janoff et al.
patent: 5415869 (1995-05-01), Straubinger et al.
patent: 5424073 (1995-06-01), Rahman et al.
patent: 5534499 (1996-07-01), Ansell
patent: 5554382 (1996-09-01), Castor
patent: 5565478 (1996-10-01), Kohn et al.
patent: 5621001 (1997-04-01), Canetta et al.
patent: 5641803 (1997-06-01), Carretta et al.
patent: 5648090 (1997-07-01), Rahman et al.
patent: 5665761 (1997-09-01), Canetta et al.
patent: 5670537 (1997-09-01), Canetta et al.
patent: 5683715 (1997-11-01), Boni et al.
patent: 5696153 (1997-12-01), Ainsworth et al.
patent: 5756537 (1998-05-01), Gill
patent: 5919816 (1999-07-01), Hausheer et al.
patent: 5994409 (1999-11-01), Stogniew et al.
patent: 6066331 (2000-05-01), Barenholz et al.
patent: 6090955 (2000-07-01), Reszka et al.
patent: 6118011 (2000-09-01), Mayhew et al.
patent: 6146659 (2000-11-01), Rahman
patent: 6461637 (2002-10-01), Rahman
patent: 2132711 (1993-09-01), None
patent: 2153326 (1995-05-01), None
patent: 2294981 (1999-01-01), None
patent: 0750910 (1997-01-01), None
patent: 0776202 (2000-05-01), None
patent: 217839 (1993-01-01), None
patent: P9903952 (1997-09-01), None
patent: 2-503558 (1990-10-01), None
patent: 6-329533 (1994-11-01), None
patent: 8-034745 (1996-02-01), None
patent: 8-508046 (1996-08-01), None
patent: 9-315978 (1997-12-01), None
patent: WO 82/03769 (1982-11-01), None
patent: WO 88/09168 (1988-12-01), None
patent: WO 93/18751 (1993-09-01), None
patent: WO 95/13053 (1995-05-01), None
patent: WO 96/15774 (1996-05-01), None
patent: WO 96/21658 (1996-07-01), None
patent: WO 97/10234 (1997-03-01), None
patent: WO 00/01366 (2000-01-01), None
Pharmaceutical Research, vol. 11, No. 2, 1994, pp. 206-212, XP000874375 “A Mixed Micellar Formulation Suitable for the Parenteral Administration of Taxol”.
Agata et al., “Anti-Tumor Activity of Docetaxel in Non-small Cell Lung Cancer Xenografts is Potentiated by NM-3, an Angiogenesis Inhibitor,”ILEX Products, Inc., Abstract No. 2752.
Ali et al., “Hyrolyzable Hydrophobic Taxanes: Synthesis and Anti-Cancer Activities,”Anti-Cancer Drugs, 12, 117-128 (2001).
Essayan et al., “Successful Parenteral Desensitization to Paclitaxel,”J. Allergy Clin. Immunol., 97(1), 42-46 (1996).
Gelderblom et al., “Influence of Cremophor EL on the Bioavailability of Intraperitoneal Paclitaxel,”Clinical Cancer Research, 8, 1237-1241 (2002).
Henningsson et al., “Mechanism-Based Pharmacokinetic Model for Paclitaxel,”J. of Clinical Oncology, 19(20), 4065-4073 (2001).
Holton et al., “Oral Anti-Tumor Activity of TL00139 (MAC-321) A New Taxane,”Annual Meeting of the American Association for Cancer Research, Abstact No. 2732, (2003).
Longley et al., “In Vitro Mechanism of Action Studies With the Taxane Analog—TL00139 (MAC-321),”Annual Meeting of the American Association for Cancer Research, Abstact No. 2733, (2003).
Marty et al., “A Comparison of Docetaxel and Paclitaxel Against Adult Human Solid Tumor Xenografts in Nude Mice,”IDD, Abstract No. 2757 (2003).
Southwell et al., “Antitumor Activity of Taxotere and Paclitaxel Against Three Human Pediatric Tumor Xenograft Models,”IDD, Abstract No. 2759 (2003).
Sparreboom et al., “Preclinical Pharmacokinetics of Paclitaxel and Docetaxel,”Anti-Cancer Drug, 9, 1-17 (1998).
Sparreboom et al., “Tissue Distribution, Metabolism and Excretion of Paclitaxel in Mice,”Anti-Cancer Drugs, 7, 78-86 (1996).
Sparreboom et al., “Introduction: Recent Topics in the Clinical Pharmacology of Taxanes that Might Change Future Perspectives,”Investigational New Drugs, 19, 111-112 (2001).
Sparreboom et al., “Cremophor EL-mediated Alteration of Paclitaxel Distribution in Human Blood: Clinical Pharmacokinetic Implications,”Cancer Research, 59, 1454-1457 (1999).
Zuylen et al., “Role of Formulation Vehicles in Taxane Pharmacology,”Investigational New Drugs, 19, 125-141 (2001).
Bonadonna, Annals of Oncology, 3, 417-418 (1992).
Devries, Annals of Oncology, 3, 419-421 (1992).
Hoeprich, “Clinical Use of Amphotericin B and Derivatives: Lore, Mystique and Fact,”Clinical Infectious Disease, 14(Suppl 1), S114-S119 (1992).
Johnson, “Taxol,”Physicians' Desk Reference, PDR 54thEds., 881-887 (2000).
“Liposomes” Ed. By Ostro, Marcel Dekker, Inc., Chp. 9, 227-338 (1987).
Petit et al., “In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating,”J. of Antimicrobial Chemotherapy, 42, 779-785 (1998).
Romanellie et al., “In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems,”Cancer Chemother Pharmacol., 41, 385-390 (1998).
Riondel et al., In Vivo, 6, 23-27 (1992).
Rahman et al., Cancer Research, 42, 1817-1825 (1982).
Rahman et al., Cancer Chemother. Pharmacol., 16, 22-27 (1986).
Rahman et al., Chemical Abstracts, Abstract No. 104(102092), (Mar. 31, 1986).
Ostro, American Journal Hosp. Pharm., 46, 1576-1587 (1989).
Rosa, Transplant Biochem. Model Syn. Res., 243-256 (1982).
Brown et al., “A phase I trial of Taxol given by a 6-hour intravenous infusion,”J. Clin. Oncol., 9 (7), 1261-1267 (Jul. 1991).
Donehower et al., “Phase I trial of Taxol in patients with advanced cancer,”Cancer Treat. Rep., 71 (12), 1171-1177 (Dec. 1987).
Eisenhauer et al., “European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion,”J. Clin. Oncol., 12 (12), 2654-2666 (Dec. 1994).
Gianni et al., “Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans,”J. Clin. Oncol., 13 (1), 180-190 (Jan. 1995).
Huizing et al., “Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients,”J. Clin. Oncol., 11 (11), 2127-2135 (Nov. 1993).
Onyuksel et al.,Pharmaceutical Research, 11(2), 206-212 (1994).
U.S. Appl. No. 10/266,030, filed Oct. 7, 2002, Rahmen.
McGuire et al., “Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms,”Ann. Intern. Med., III(4), 273-279 (Aug. 15, 1989).
Saville et al., “Phase II study of paclitaxel (Taxol™) for the treatment of HIV-associated Kaposi's sarcoma (KS),”Blood, 84 (10, Suppl. 1), 248a (Abstract 977) (Nov. 15, 1994).
Saville et al., “Treatment of HIV-associated Kaposi's sarcoma with paclitaxel,”The Lancet, 346, 26-28 (Jul. 1, 1995).
Straubinger et al., “Novel Taxol formulations: Taxol-containing liposomes,”Monogr. Natl. Cancer Inst., 15, 69-78 (1993).
Wiernik et al., “Phase I trial of Taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma,”J. Clin. Oncol., 5 (8), 1232-1239 (Aug. 1987).
Ksihore Gollamudi S.
Neopharm, Inc.
LandOfFree
Method of administering liposomal encapsulated taxane does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of administering liposomal encapsulated taxane, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of administering liposomal encapsulated taxane will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3915416